Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.615
-0.005 (-0.19%)
Aug 6, 2026, 12:09 PM EDT - Market open
Ovid Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 94.06 | 13.15 | 26.3 | 27.04 | 44.87 | 187.8 |
Short-Term Investments | 61.46 | 56.48 | 26.77 | 78.79 | 84.13 | - |
Cash & Short-Term Investments | 155.52 | 69.64 | 53.08 | 105.83 | 129 | 187.8 |
Cash Growth | 261.71% | 31.20% | -49.85% | -17.96% | -31.31% | 160.71% |
Other Current Assets | 4.62 | 4.73 | 2.87 | 3.76 | 2.38 | 2.68 |
Total Current Assets | 160.15 | 74.37 | 55.94 | 109.6 | 131.38 | 190.48 |
Net Property, Plant & Equipment | 11.52 | 11.86 | 13.23 | 14.66 | 16.07 | 0.24 |
Long-Term Investments | 52.04 | 62.77 | 20.97 | 17.63 | 5.62 | 1.63 |
Other Long-Term Assets | 1.93 | 1.93 | 2.02 | 2.14 | 2.19 | 2.19 |
Total Assets | 225.63 | 150.93 | 92.17 | 144.03 | 155.27 | 194.54 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.88 | 1.96 | 3.19 | 3.7 | 1.95 | 7.13 |
Accrued Expenses | 5.41 | 4.9 | 5.99 | 6.52 | 4.5 | 7.67 |
Current Portion of Leases | 1.46 | 1.43 | 1.34 | 1.25 | 0.53 | - |
Total Current Liabilities | 15.75 | 8.29 | 10.52 | 11.47 | 6.99 | 14.8 |
Long-Term Leases | 11.61 | 11.99 | 13.42 | 14.76 | 16 | - |
Other Long-Term Liabilities | - | - | - | 30 | - | - |
Total Long-Term Liabilities | 11.61 | 11.99 | 13.42 | 44.76 | 16 | - |
Total Liabilities | 27.36 | 20.27 | 23.94 | 56.23 | 22.99 | 14.8 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Preferred Stock | - | - | - | - | 0 | 0 |
Common Stock | 0.17 | 0.13 | 0.07 | 0.07 | 0.07 | 0.07 |
Additional Paid-in Capital | 537.23 | 452.45 | 372.49 | 365.59 | 357.77 | 351.03 |
Accumulated Other Comprehensive Income | -0.42 | -0.2 | -0.04 | 0 | -0.04 | - |
Retained Earnings | -338.7 | -321.71 | -304.3 | -277.87 | -225.53 | -171.36 |
Shareholders' Equity | 198.27 | 130.66 | 68.23 | 87.8 | 132.27 | 179.75 |
Total Liabilities & Equity | 225.63 | 150.93 | 92.17 | 144.03 | 155.27 | 194.54 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 13.07 | 13.42 | 14.76 | 16 | 16.54 | 0 |
Net Cash (Debt) | 142.45 | 56.22 | 38.32 | 89.83 | 112.47 | 187.8 |
Net Cash Growth | 398.68% | 46.70% | -57.34% | -20.13% | -40.11% | 160.71% |
Net Cash Per Share | 1.58 | 0.76 | 0.54 | 1.27 | 1.60 | 2.76 |
Book Value | 198.27 | 130.66 | 68.23 | 87.8 | 132.27 | 179.75 |
Book Value Per Share | 2.20 | 1.77 | 0.96 | 1.24 | 1.88 | 2.64 |
Tangible Book Value | 198.27 | 130.66 | 68.23 | 87.8 | 132.27 | 179.75 |
Tangible Book Value Per Share | 2.20 | 1.77 | 0.96 | 1.24 | 1.88 | 2.64 |